MR
Maravai LifeSciences Holdings, Inc.
MRVI · NASDAQ
$7.17 +2.65% (+$0.18)
1M -14.95%
Market Cap $1.04B
P/E Ratio -
Div. Yield -
ROE 35.42%
Bulios Fair Price
$5.69
20.6% downside
Current Price
$7.17
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MRVI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
35 /100
Fair P/S 4.98x
P/B 5.08x
P/E N/A
Growth
0 /100
Declining Rev. growth 40.53%
Book val. growth 26.97%
EPS growth N/A
Profitability
43 /100
Moderate Gross margin 34.61%
Net margin 37.07%
Op. margin 46.02%
Quality
39 /100
Average ROIC 16.91%
ROE 35.42%
ROA 12.82%
Debt
50 /100
Moderate Debt/Equity 0.86x
Current ratio 4.05x
Int. coverage -4.70x
Stability
35 /100
Moderate Beta 0.61x
Rev. volatility 29.12%
EPS volatility 89.16%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRVI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Bernd Brust
Employees
415
Headquarters
San Diego
Upcoming events
05 NOV
Earnings
Upcoming earnings report